Virtual Screening and Characterization of AN‐329/11627212 as a Novel Inhibitor Disrupting the EED‐H3K27me3 Interaction
Chemistry & Biodiversity · 2026-04 · 23 (4)
DOI: 10.1002/cbdv.71171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 01.04.2026. Verfasst von Ning Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China. Hauptthemen laut MEDLINE: Polycomb Repressive Complex 2, Histones, Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Strategic Priority Research Program of the Chinese Academy of Sciences, National Natural Science Foundation of China, Research Project of Yunnan Province.
Abstract (Originalsprache)
The key epigenetic regulator polycomb repressive complex 2 (PRC2) is dysregulated in multiple cancers. While most therapeutic strategies target its catalytic EZH2 subunit, inhibition of its allosteric EED subunit offers a potential strategy for overcoming emerging drug resistance. Here, we identify and characterize AN‐329/11627212, a novel EED‐targeting compound, through structure‐based virtual screening. Biochemical and biophysical analyses confirm its direct binding to EED. Strikingly, x‐ray crystallography reveals that AN‐329/11627212 induces dissociation of the pre‐bound EED‐H3K27me3 complex, consistent with a “hit‐and‐run” inhibitory mechanism. Detailed molecular docking revealed that AN‐329/11627212 embeds itself within EED's allosteric H3K27me3‐binding pocket. Functionally, AN‐329/11627212 exhibited anti‐proliferative activity in PRC2‐dependent cancer cell lines, most potently against HCT116 colon cancer cells. Our work identifies AN‐329/11627212 as a novel chemotype that acts by dissociating the EED‐H3K27me3 complex, providing a foundation for developing next‐generation anti‐tumor agents targeting PRC2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China.
- University of Chinese Academy of Sciences, Beijing, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute of Advanced Study, UCAS, Hangzhou, China.
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID-Profile: Yan Liu, Shenghong Li, Lihu Gong
Förderung
- Strategic Priority Research Program of the Chinese Academy of Sciences
- National Natural Science Foundation of China
- Research Project of Yunnan Province
- Introducing Talents Start-up Fund of Kunming Institute of Botany, Chinese Academy of Sciences
- Fund of State Key Laboratory of Phytochemistry and Natural Medicines
Zitieren
APA
Zhou, N., Zuo, Z., Cao, H., Tian, C., Liu, Y., Li, S., & Gong, L. (2026). Virtual Screening and Characterization of AN‐329/11627212 as a Novel Inhibitor Disrupting the EED‐H3K27me3 Interaction. Chemistry & Biodiversity, 23(4). https://doi.org/10.1002/cbdv.71171
Vancouver
Zhou N, Zuo Z, Cao H, Tian C, Liu Y, Li S, et al. Virtual Screening and Characterization of AN‐329/11627212 as a Novel Inhibitor Disrupting the EED‐H3K27me3 Interaction. Chemistry & Biodiversity. 2026;23(4). doi:10.1002/cbdv.71171
BibTeX
@article{Zhou2026,
author = {Zhou, Ning and Zuo, Zhili and Cao, Haiqiong and Tian, Chengwen and Liu, Yan and Li, Shenghong and Gong, Lihu},
title = {Virtual Screening and Characterization of AN‐329/11627212 as a Novel Inhibitor Disrupting the EED‐H3K27me3 Interaction},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {4},
doi = {10.1002/cbdv.71171}
}
EUVIMED